Lipocine Chairman Dana Ono cited Grissinger’s extensive background in mergers, acquisitions, and licensing as the primary driver for the move. As the company looks to advance its clinical assets, Grissinger is expected to provide critical oversight in navigating corporate development and commercial partnerships. His career includes senior leadership roles at Johnson & Johnson, where he managed the Worldwide Pharmaceutical Licensing and M&A divisions, as well as a 12-year tenure at Ciba-Geigy.
In section Releases
Lipocine Adds Veteran Dealmaker Michael J. Grissinger to Board
Michael J. Grissinger, a pharmaceutical industry veteran with two decades of experience at Johnson & Johnson, has joined the Board of Directors at Salt Lake City-based Lipocine Inc. The appointment, effective August 3, signals a strategic pivot toward aggressive dealmaking and partnership development for the firm's oral delivery pipeline.
Grissinger currently serves on the boards of Aprea Therapeutics and Adicet Bio, alongside advisory roles for private biotech firms. His arrival comes as Lipocine continues to develop its portfolio, which spans treatments for postpartum depression, epilepsy, and obesity, as well as its FDA-approved testosterone deficiency therapy, TLANDO. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from the Fox School of Business at Temple University.
Comments (0)
No comments yet. Be the first!